Bristol Myers Squibb delivered a clean beat on both lines in the third quarter. EPS of $1.35 topped the $1.21 consensus by 11.6%, and revenue of $13.069 billion beat the $12.56 billion estimate by 4.1%. Revenue grew 6.9% year over year, a clear acceleration from roughly 1% growth in the first quarter and a flat fourth quarter of fiscal 2025. Management also raised full-year revenue guidance for the third consecutive quarter. The headline, however, does not settle the investment debate. Earnings still fell 17.2% from a year ago, and several engines meant to carry BMS past its patent cliffs slowed. The central tension is a stronger near-term financial picture set against a growth portfolio that is losing some speed just as Eliquis exclusivity begins to erode.

The quality of the beat deserves some scrutiny. Much of the top-line strength came from the legacy business, not the newer franchises. Eliquis grew 26% to about $4.7 billion. Management now expects the legacy portfolio to decline only 3-5% this year, compared with the 12-16% decline it guided at the start of the year. That outperformance is real cash. It is also cash from a product that loses EU exclusivity in the fourth quarter, and management reiterated a $1.5-2 billion Eliquis step-down in 2027. The year-over-year earnings decline appears to reflect, at least in part, a $0.58-per-share acquired IPR&D and licensing charge taken in the quarter. Margins also softened: gross margin fell to 68.4% from 71.4% in the second quarter, which management attributed to mix and a one-time contract termination charge. Full-year gross margin guidance was maintained. Full-year non-GAAP EPS guidance is now $6.35-6.55, with the charge absorbed. Management said the underlying midpoint rose about $0.15, well above the original $6.05-6.35 range.

Beneath the surface, the growth portfolio decelerated for a second straight quarter. Growth slowed to 12% from 14% in the second quarter and 15% in the fourth quarter of fiscal 2025.

• **Camzyos** growth slowed to 42% from 59%, partly because of an inventory drawdown.
• **Cobenfi** was the clearest disappointment. Revenue slipped sequentially to $57 million from $63 million on destocking. Prescription growth cooled to about 3-4% quarter over quarter from roughly 15%, and the call acknowledged ongoing titration and repeat-prescribing challenges.
• **Opdivo** fell 6%, steeper than the prior quarter's 4% decline, as patients convert to Qvantig.

There were genuine bright spots. Breyanzi grew 48% and Reblozyl 22%. Qvantig reached $334 million, up 28% sequentially, with conversion near 17%. Eight growth medicines now annualize above $1 billion. Management's tone turned noticeably more confident, with references to 'real momentum' and 'wind at our back.'

The pipeline is where the story improved most. On the prior call, management framed these programs as pending binary events. This quarter brought:

• accelerated approval of iberdomide (Zimbexis), the first approved CELMoD in multiple myeloma;
• four positive registrational readouts in roughly two months: iberdomide PFS, admilpirant in IPF, the RAISE-101 interim in GEP-NETs, and arlo-cel in post-BCMA myeloma.

The wins were not unqualified. Admilpirant's 120 mg dose missed statistical significance, which clouds the first-quarter 2027 PPF readout. The zola-cel autoimmune CAR-T program remains paused after a disclosed fatal event. Milvexian AF and the Cobenfi ADEPT readouts remain pushed into 2027. Near-term catalysts include milvexian SSP and Sotyktu lupus data by year-end and a May 13, 2027 PDUFA date for mezigdomide. Investors also questioned whether BMS's business-development spending lags its peers, even with cash rising to about $13 billion and quarterly operating cash flow reaching about $4.2 billion.

Investors entered the report less enthusiastic than they were three months ago. Earnings Whispers sentiment remained positive but weakened meaningfully, falling from 0.36 to 0.20. Price action matched that cooling. Shares hit a 52-week high of $68.64 in mid-August, then slid to a $56.15 low on October 13. They closed at $60.57 ahead of the report, down 3.4% since the open following the July release and just 1.2% above the 200-day moving average. The trend readings are mixed: momentum is positive while AVWAP remains negative, consistent with a stock that has rebounded off its lows without reclaiming its summer strength.

The bottom line is that BMS gave investors more than enough to defend the near-term thesis: a decisive beat, accelerating revenue, a third straight guidance raise and a pipeline that converted pending binary events into approvals and positive data. Bears still have legitimate ammunition. The growth portfolio is decelerating, Cobenfi's launch has stalled, margins dipped and much of the upside came from Eliquis, which faces a known cliff. Whether the new launches can scale quickly enough to absorb the 2027 step-down remains the question this quarter did not answer.